EP Patent

EP0547000A1 — Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound

Assigned to Novartis AG · Expires 1993-06-16 · 33y expired

What this patent protects

A pharmaceutical dosage form comprising an HMG-CoA reductase inhibitor compound, e.g. , fluvastatin sodium, is disclosed which is stabilized against pH-related degradation by an alkaline stabilizing medium capable of imparting a pH of at least 8 to an aqueous solution or dispers…

USPTO Abstract

A pharmaceutical dosage form comprising an HMG-CoA reductase inhibitor compound, e.g. , fluvastatin sodium, is disclosed which is stabilized against pH-related degradation by an alkaline stabilizing medium capable of imparting a pH of at least 8 to an aqueous solution or dispersion of the composition.

Drugs covered by this patent

Patent Metadata

Patent number
EP0547000A1
Jurisdiction
EP
Classification
—
Expires
1993-06-16
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.